(NASDAQ: MDXG) Mimedx Group's forecast annual revenue growth rate of 11.82% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 39.22%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.52%.
Mimedx Group's revenue in 2024 is $321,477,000.On average, 3 Wall Street analysts forecast MDXG's revenue for 2024 to be $52,733,089,849, with the lowest MDXG revenue forecast at $52,170,239,100, and the highest MDXG revenue forecast at $53,376,767,728. On average, 3 Wall Street analysts forecast MDXG's revenue for 2025 to be $59,750,354,404, with the lowest MDXG revenue forecast at $58,783,368,000, and the highest MDXG revenue forecast at $61,603,500,080.
In 2026, MDXG is forecast to generate $65,638,978,293 in revenue, with the lowest revenue forecast at $65,638,978,293 and the highest revenue forecast at $65,638,978,293.